secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-12-17T23:59:59+00:00
Accession:  0001104659-25-121749
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma ratutrelvir shows fewer adverse events and no viral rebound in interim Phase 2 COVID-19 data vs PAXLOVID
--------------------------------------------------------------------------------

- Interim analysis of 37 patients: 25 on ratutrelvir 600 mg once daily 10 days, 12 on PAXLOVID 5-day regimen.
- No viral rebound observed in ratutrelvir arm; 1 rebound (8.3%) in PAXLOVID arm.
- 24% of ratutrelvir cohort were PAXLOVID-ineligible; symptom improvement consistent with broader group.
- Adverse events lower: 7.6% mild dyspepsia on ratutrelvir vs 30% dysgeusia/dizziness/dyspepsia on PAXLOVID.
- Final data expected January 2026; enrollment >50% of planned 90-patient study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925121749/0001104659-25-121749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925121749/tm2533729d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-121749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer